Χώρα: Ηνωμένο Βασίλειο
Γλώσσα: Αγγλικά
Πηγή: MHRA (Medicines & Healthcare Products Regulatory Agency)
Glycerol
McNeil Products Ltd
A06AX01
Glycerol
150microlitre/1ml
Oral solution
Oral
No Controlled Drug Status
Valid as a prescribable product
BNF: 03090200; GTIN: 3574660518948
3 + months Dry & Tickly Cough Relief 3 + months COLOUR & SUGAR FREE SYRUP INFANT GLYCEROL Apple flavour S P O O N SYRUP INFANT GLYCEROL INFAN 16-0423 HOW TO USE THIS MEDICINE Check the information below to see how much medicine to give. • For oral use only. • Do not give more medicine than the carton (and/or label) tells you to. Babies under 3 months Children from 3 months to 5 years Do not give to babies under 3 months. AGE HOW MUCH CHILDREN 3 MONTHS TO One 5 ml spoonful 1 YEAR CHILDREN 1 - 5 YEARS Two 5 ml spoonfuls • Give the dose 3 or 4 times within 24 hours, if needed. • If symptoms persist for more than 3 days, consult your doctor. IF ANYONE HAS TAKEN TOO MUCH If anyone has taken too much of this product, contact a doctor or your nearest Accident & Emergency Department (Casualty), taking this pack with you. IF YOU FORGET TO GIVE THE MEDICINE If you forget a dose, give the next dose when needed. DO NOT give a double dose. TALK TO YOUR DOCTOR OR PHARMACIST If your child has an intolerance to some sugars. SOME OF THE INGREDIENTS CAN CAUSE PROBLEMS • This product contains maltitol. If you have been told by your doctor that your child has an intolerance to some sugars, contact your doctor before using this product. This should be taken into account in patients with diabetes. • Maltitol may have a mild laxative effect. Calorific value 2.3 kcal/g maltitol. POSSIBLE SIDE-EFFECTS This medicine is unlikely to cause side-effects unless your child is allergic to the ingredients. If your child experiences any side-effects or you are not sure about anything, talk to your doctor or pharmacist. Reporting of side-effects: If you get any side-effects, talk to your doctor, pharmacist or nurse. This includes any possible side-effects not listed on this carton. You can also report side-effects directly via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard By reporting side-effects you can help provide more information on the safety of this medicine. STORING THIS MEDICINE Keep out of the sight and reach of childr Διαβάστε το πλήρες έγγραφο
OBJECT 1 CALCOUGH INFANT SYRUP Summary of Product Characteristics Updated 22-Apr-2016 | McNeil Products Ltd 1. Name of the medicinal product Benylin Children's Apple Flavour Cough Syrup or CalCough Infant Syrup or Benylin Infant's Cough Syrup 2. Qualitative and quantitative composition Active ingredient Glycerol % v/v 15.0 ml/5ml 0.75 Excipient with known effect: Maltitol liquid (E965) For the full list of excipients, see section 6.1 3. Pharmaceutical form Syrup A clear colourless syrup with an apple flavour. 4. Clinical particulars 4.1 Therapeutic indications For the relief of dry tickly coughs. 4.2 Posology and method of administration Posology Children 3 months - 1 year: one 5ml spoonful three to four times a day. Children 1 to 5 years: two 5ml spoonfuls three to four times a day. Children under 3 months: not recommended. Method of administration For oral use. 4.3 Contraindications Hypersensitivity to the active substance or to any of the ingredients listed in section 6.1. Not recommended for children under 3 months. Patients with rare hereditary problems of fructose intolerance should not take this medicine. 4.4 Special warnings and precautions for use If symptoms persist for more than 3 days consult your doctor. Keep all medicines out of the reach of children. 4.5 Interaction with other medicinal products and other forms of interaction No clinically significant drug interactions. 4.6 Fertility, pregnancy and lactation Not applicable. 4.7 Effects on ability to drive and use machines No or negligible influence. 4.8 Undesirable effects Maltitol may have a mild laxative effect. REPORTING OF SUSPECTED ADVERSE REACTIONS Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard 4.9 Overdose Overdosage with this product may possibly cause diarrhoea. Treatment sh Διαβάστε το πλήρες έγγραφο